

Niemann-Pick disease

Dr. Eugen Mengel

in collaboration with


Prof. Dr. Michael Beck †

Prof. Dr. Klaus Harzer

Prof. Dr. Thorsten Marquardt

Dr. Janine Reunert

Dr. Heiko Runz



Niemann-Pick Disease



UNI-MED Verlag AG
Bremen - London - Boston

Mengel, Eugen:

Niemann-Pick disease/Eugen Mengel.-

1st edition - Bremen: UNI-MED, 2022

(UNI-MED SCIENCE)

ISBN 978-3-8374-6447-4

© 2022 by UNI-MED Verlag AG, D-28323 Bremen,
International Medical Publishers (London, Boston)
Internet: www.uni-med.de, e-mail: info@uni-med.de

Printed in Europe

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way and storage in data banks. Violations are liable for prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature.

MEDICINE - STATE OF THE ART

UNI-MED Verlag AG, one of the leading medical publishing companies in Germany, presents its highly successful series of scientific textbooks, covering all medical subjects. The authors are specialists in their fields and present the topics precisely, comprehensively, and with the facility of quick reference in mind. The books will be most useful for all doctors who wish to keep up to date with the latest developments in medicine.

Preface

It's been a few years since I visited Seville and especially the magnificent Casa de Pilatos from the 15th century in the old city center. The building represents a wonderful synthesis of Moorish and Spanish cultures. A Janus head can be found in the inner courtyard. The two faces look curiously, but also a little fearfully, in opposite directions. Niemann-Pick disease spontaneously came to my mind. The sculpture seems to be of one person, but the two faces represent two different identities. This is the exact association I have with Niemann-Pick disease. We have to distinguish the sphingomyelinase deficiency, Niemann-Pick disease type A & B, from the intracellular lipid transport defect, Niemann-Pick disease type C. This book presents these two entities as genetically and molecular-biologically distinct diseases, and for that reason, they will be discussed separately in the following. The fact that the Janus faces look in opposite directions is a meaningful symbol that the different biology of the diseases also requires different therapeutic approaches. While the sphingomyelinase deficiency suggests the therapeutic principle of enzyme replacement, therapeutic substrate reduction must be considered in Niemann-Pick type C.



Families and patients, as well as their physicians, often ask me for an English-language edition of our book on Niemann-Pick disease. New findings in the field of basic research, a better understanding of clinical features, improved diagnostic options – especially to differentiate more easily between Niemann-Pick type C and sphingomyelinase deficiency (Niemann-Pick type A & B) –, and specific new therapeutic approaches are further arguments for creating such an edition. Prof. Michael Beck and I had already revised and updated the previous chapters for the second German-language edition that has just been published. At the suggestion of colleagues, we have added an additional chapter on “Diagnosis”. This chapter in particular can be used as a quick reference work. The chapter shows which clinical symptoms corroborate a suspected diagnosis and how the diagnosis is confirmed in the laboratory.

This edition is especially dedicated to all patients with a Niemann-Pick disease and the active Niemann-Pick advocacy group.

This edition could be realized with the support of the company Gen-Orph. Thank you very much!

Hochheim, December 2021

Eugen Mengel

In addition, I dedicate this book to my chief, teacher, advisor, colleague, role model, comrade-in-arms, and friend Professor Michael Beck, who passed away too soon in September 2022.

Foreword

Eugen Mengel did his studies of medicine at Philipps-University, Marburg, and Goethe-University in Frankfurt from October 1986 to September 1992. Since 1994, the medical practice has been conducted in the pediatric setting with infants, toddlers, school-age children, and adolescents and adults in some trials.

In 1994 Eugen Mengel joined the lysosomal storage disorders group named Villa metabolica of Michael Beck UMC Mainz. He was the responsible consultant for Gaucher and Niemann-Pick outpatient clinic since 1999 and later on Pompe. From 2001 to 2019 he assisted as consultant in pediatric inborn errors of metabolism in the Children's Hospital, University of Mainz (Germany).

As sub investigator and deputy of Michael Beck he has worked on international multicenter trials for ERT in Fabry disease, Mannosidosis, Pompe disease, MPS II, MPS VI and MPS I and assisted the outpatient clinic for general metabolic, MPS, Gaucher, Niemann-Pick and Fabry patients. As principal investigator he has acted in international trials concerning NPC, ASMD, Pompe disease, Gaucher disease, LALD, Mannosidosis and Morquio disease. He has worked on biochemical diagnostic LSD laboratory from the beginning with extensive knowledge in the clinical and biochemical diagnostics of LSDs. In 2001 he received the certification for Investigator in clinical trials: KKS in Johannes-Gutenberg-Mainz. Since 2002 continuous activity as Principle Investigator in more than 25 studies according to AMG in the field of lysosomal diseases.

He has participated on student's education in pediatric hematological, oncological and metabolic diseases and given lectures about sphingolipidosis and MPS for students of medicine in biochemistry. He has been a colossal teacher, with a passionate love for medicine, metabolic diseases, and great affection for his students. One of its great virtues is his ability to synthesize and structure the most complicated ideas, concepts, and mechanisms. He makes what is difficult easy. He is a great communicator and a great teacher.

He is an active member of the SSIEM, ESGLD and EWGGD and also Board Member of several company Registries in Pompe disease (Sanofi Genzyme), Gaucher disease (Sanofi Genzyme) and Niemann-Pick type C (Actelion). As for the human side, he is an excellent person, of good character, kind and always willing to collaborate. His renowned reputation as a physician dedicated to metabolic diseases is adorned by his human qualities.

Since 2019 he is the Principle investigator, founder and CEO of the SphinCS GmbH & SphinCS Lyso non-profit UG, independent institute of clinical science in LSDs.

Barcelona, June 2022

Mercedes Pineda

Authors

Prof. Dr. Michael Beck †
SphinCS - Clinical Science for LSD
Geheimrat-Hummel-Platz 2
65239 Hochheim, Germany

Chapters 1., 3.

Prof. Dr. Klaus Harzer
Universitätsklinik für Kinder- und Jugendmedizin Tübingen
Neurometabolisches Labor
Hoppe-Seyler-Str. 1
72076 Tübingen, Germany

Chapter 2.

Prof. Dr. Thorsten Marquardt
Universitätsklinikum Münster
Klinik für Kinder- und Jugendmedizin
Albert-Schweitzer-Campus 1
48149 Münster, German

Chapter 4.2.2.

Dr. Eugen Mengel
SphinCS - Clinical Science for LSD
Geheimrat-Hummel-Platz 2
65239 Hochheim, German

Chapters 1., 2., 4., 5.

Dr. Janine Reunert
Universitätsklinikum Münster
Klinik für Kinder- und Jugendmedizin
Albert-Schweitzer-Campus 1
48149 Münster, German

Chapter 4.2.2.

Dr. Heiko Runz
Medical Director, Genetics at Biogen
Cambridge, Massachusetts, USA

Chapter 3.

Contents

1.	Historical aspects of Niemann-Pick disease	12
2.	Biochemistry of Niemann-Pick disease	18
2.1.	Introduction and definitions.	18
2.2.	Missing or pathological products of "Niemann-Pick genes"	19
2.3.	Biochemical foundations of diagnosing Niemann-Pick diseases	19
2.3.1.	Niemann-Pick disease, SMPD1-associated.	19
2.3.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2).	19
2.3.3.	Chitotriosidase activity in plasma	20
2.3.4.	Determination of oxysterols	20
2.3.5.	Determination of lyso-sphingomyelin-509 (lyso-SM-509)	21
2.3.6.	Determination of bile acids	21
2.4.	Biochemistry of Niemann-Pick diseases that is pathogenetically relevant or suspected to be significant	21
2.4.1.	Niemann-Pick disease, SMPD1-associated.	21
2.4.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2) in general	22
2.4.3.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2), central nervous system	24
2.5.	Animal models.	25
2.5.1.	Niemann-Pick disease, SMPD1-associated.	25
2.5.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1, NPC2).	25
2.6.	Therapeutic concepts for the possible influence of pathogenetically significant metabolic changes.	26
2.6.1.	Niemann-Pick disease, SMPD1-associated.	26
2.6.2.	Niemann-Pick disease, transport protein deficiency-associated (NPC1)	26
3.	Genetics of Niemann-Pick disease	34
3.1.	Niemann-Pick disease type A/B (NPA/B) [MIM: 257200/607616]	34
3.1.1.	SMPD1 gene and ASM protein [HGNC Gene-ID: 11120].	34
3.1.2.	SMPD1 variants.	34
3.2.	Niemann-Pick disease type C (NPC) [MIM: 257220/607625]	35
3.2.1.	NPC1 gene and protein [HGNC Gene-ID: 7897]	36
3.2.2.	NPC1 variants	37
3.2.3.	NPC2 gene and protein [HGNC Gene-ID: 14537]	38
3.2.4.	NPC2 variants	38
3.3.	Challenges of genetic testing in Niemann-Pick disease and outlook.	38
3.4.	Genetic databases for Niemann-Pick diseases.	39
4.	Diagnosis of Niemann-Pick disease type C (NPC)	44
4.1.	Recommendations for differential diagnosis and initial diagnosis.	44
4.2.	Clinical diagnosis and key findings in NPC	46
4.2.1.	Neuropsychological diagnosis and key findings	46
4.2.2.	Laboratory diagnostics and biomarkers	47

4.3.	Significance of genetic testing in NPC	50
4.3.1.	Next-generation sequencing (NGS) and gene panels	52
4.3.2.	Differentiation from acid sphingomyelinase deficiency (ASMD)	52
4.4.	Differential diagnosis of similar lysosomal diseases.....	54
5.	Clinical manifestation	58
5.1.	Niemann-Pick disease type A and type B.....	58
5.2.	Niemann-Pick type C disease	62
5.2.1.	Perinatal type	63
5.2.2.	Infantile type.....	64
5.2.3.	Late-infantile type.....	64
5.2.4.	Juvenile classic type.....	67
5.2.5.	Adult type	70
5.2.6.	Psychiatric manifestations in Niemann-Pick type C disease.....	71
6.	Management and treatment of Niemann-Pick diseases	80
6.1.	Management and treatment of Niemann-Pick type A/B disease	80
6.1.1.	Supportive care	80
6.1.2.	Causal therapeutic approaches	81
6.1.3.	Future therapy options	82
6.2.	Management and treatment of Niemann-Pick type C disease.....	83
6.2.1.	Miglustat.....	84
6.2.2.	Bone marrow and liver transplantations.....	85
6.2.3.	Treatment of extrapyramidal symptoms, spasticity, cataplexy and epilepsy.....	85
6.2.4.	Substances in preclinical and experimental studies	86
	Index	87